Should MiMedx Group (NASDAQ:MDXG) Be Disappointed With Their 41% Profit?

Simply Wall St
·3 min read

Investors can buy low cost index fund if they want to receive the average market return. But in any diversified portfolio of stocks, you'll see some that fall short of the average. For example, the MiMedx Group, Inc. (NASDAQ:MDXG) share price return of 41% over three years lags the market return in the same period. Having said that, the 41% increase over the past year is good to see.

See our latest analysis for MiMedx Group

Because MiMedx Group made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

MiMedx Group actually saw its revenue drop by 6.4% per year over three years. The falling revenue is arguably somewhat reflected in the lacklustre return of 12% per year over three years, which falls short of the market return. As a general rule we don't like it when a loss-making company isn't even growing revenue.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).


If you are thinking of buying or selling MiMedx Group stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

MiMedx Group shareholders have received returns of 41% over twelve months, which isn't far from the general market return. Most would be happy with a gain, and it helps that the year's return is actually better than the average return over five years, which was 2%. Even if the share price growth slows down from here, there's a good chance that this is business worth watching in the long term. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - MiMedx Group has 2 warning signs (and 1 which can't be ignored) we think you should know about.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)